A young seedling with strong roots
Based on 13 years of experience in clinical laboratory diagnostics the AMP Diagnostics group has been founded in October 2000 with the target to offer products of highest quality as well as qualified technical and application support to users of clinical chemistry and hematology analyser systems mainly in Central and Eastern Europe.
In 2003 the product portfolio has been expanded to cover the main segments of routine diagnostics and collaboration with distributors outside Europe has been started. Today the AMP Diagnostics team cooperates with qualified distribution partners in more than 60 countries all over the world in providing qualified assistance to healthcare specialists.
That's what we are reaching for
Our business activities are based on good relationship with our partners – customers as well as suppliers. Therefore maintaining our partnerships is of essential importance for us – in good times as well as in difficult ones.
Today’s world is changing quickly. Lack of backing by long-term relationships and missing trust in basic values might result in the loss of identity. Therefore we’ll always do our utmost to keep commitments given to our partners.
Our partners trust in our expertise related to the business segment we are working in. Flexibility is not in contradiction to reliability and loyalty – in certain situation it is even a basic condition for these attributes. In our constantly changing world it is necessary to leave known pathways and look for alternative solutions in order to reach the agreed target or to keep a commitment.
The centre of our activities
Our products and services are addressed to healthcare specialists dedicated to the supply of reliable diagnostic information to physicians using the reported data as a basis for their decision concerning patients’ therapy. In daily routine they are often under pressure to report analytical results within the shortest period of time and as cost efficient as possible.
Modern technologies are a good basis to reach these sometimes contra dictionary targets. Therefore we listen carefully to our customers in order to achieve a good understanding of their demands and thus to be able to provide them with adequate solutions assisting them efficiently in performing their valuable and responsible obligations and tasks. We feel obliged to provide only products and services of best quality meeting the requirements of our customers.
Jointly reaching for the same targets
In today’s world with its high speed of innovations and technological progress it is impossible for small to medium sized companies to maintain leadership in all the different segments of clinical laboratory diagnostics. Therefore efficient collaboration with adequate partners is of essential importance to be able to offer an attractive portfolio of products and services.
Not only the product features and manufacturing skills are important criteria when choosing a collaboration partner but also certain conformity in respect to strategies, visions, values and structures. Only the efficient collaboration with our reliable partners reaching for the same targets enables us to satisfy our customers.
Essential supporters of our strategies
On the way to realisation of our targets we need the support of our employees as the most important capital – their enthusiasm, their engagement, their empathy and their determination to mutual success
Therefore the team members of AMP Diagnostics have been carefully chosen in respect to their contribution to our common goal. Team spirit and customer orientation are important general characteristics of all employees. Regular training is essential to maintain their expertise in their specific field of activities.
Challenging tasks combined with adequate responsibilities and competences will ensure that our employees are always committed to provide the best service to our customers.
The CARESS Project
The CARESS project is a joint effort of 3 research institutions from Italy and France together with 4 SME's (small and medium entities) from Austria, France and Italy to develop an accurate, easy-to-use and cost efficient technology for determination of the DPD (dihydropyrimidine dehydrogenase) activity level.
The enzyme DPD is of crucial importance in the metabolism and deactivation of 5-FU (fluorouracil), a cytostatic drug most successfully and most commonly used in treatment of breast, colon and skin cancer.
In case of a genetically caused DPD deficiency 5-FU therapy will result in severe toxic reactions, which can be even fatal at the very first dose of 5-FU. Thus simple and reliable DPD activity screening is of essential importance for early detection of serious counter-indications for 5-FU therapy.
The novelty of the proposed approach to measure the DPD activity relies on the use of a “molecular probe”, perfectly analogous to 5-FU, which interacts with the DPD in the blood in the same way as 5-FU. The protocol will be automated in the first compact, cost efficient, accurate and standard system for measuring the DPD activity, thus allowing for fast screening of DPD deficiency; this will be the immediate short term result deriving from the project.
The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013), managed by the REA - Research Executive Agency under the Grant Agreement no. 315398